JAN 20, 2022 7:00 AM PST

Nanoparticles Put To the Test: No Glow, No-Go

WRITTEN BY: Tara Fernandes

Nanoparticles—tiny spheres carrying a biologically-active cargo—have the potential to transform how we treat and prevent disease. Take the Moderna and Pfizer/BioNTech COVID-19 vaccines, for instance. These lipid nanoparticle-based vaccines shuttled viral proteins in the form of mRNA to activate the immune system. 

These and other classes of nanoparticles aren't new technologies; chemists had developed similar drug delivery systems as far back as the 1960s. One of the main barriers holding nanoparticles back as a routinely-used drug delivery modality is their low delivery rate. Scientists estimate that these ultrasmall particles only release around 1-2 percent of their cargo into cells.

It has not been easy for scientists to track whether or not a nanoparticle reaches its target cell and delivers its active ingredient. Current assessment protocols only provide information on whether the nanoparticle has reached its cellular destination. Jordan Green, a biomedical engineering expert from the Johns Hopkins University School of Medicine, led a team to develop advanced ways of tracking the location and release status of nanoparticles in the body.

The team describes their innovation in the peer-reviewed journal Science Advances.

The 'high-throughput and high-content bioassay' created by Green and colleagues can assess hundreds of different nanoparticle formulations, ranking them on their ability to make it into the cell's cytosol and deposit their cargoes. The test is powered by genetically-engineered mouse cells that glow with an orange-red fluorescent hue when a nanoparticle successfully delivers its molecular package to the cell. 

Captured fluorescence emitted by the cells treated with nanoparticles is analyzed with a specially-designed computer program. With this advanced assessment tool, drug developers can quickly weigh up the efficiency of many nanoparticle formulations at once, data that helps them guide their selection of which formulations may make better therapeutics.

The researchers went on to test whether the data from the cell assay mirrors how nanoparticles behave in the body. To do this, they performed a series of experiments in mice that were given biodegradable nanoparticles loaded with mRNA for a glowing chemical called luciferase. If nanoparticles released luciferase mRNA into cells, they would express the protein, eventually radiating light.

To the team's excitement, the "best performing" formulations as measured using the computer program correlated with those that achieved high levels of gene delivery in mice. This observation confirmed that their innovation was a robust predictor of nanoparticle dynamics in the body.

This is only the beginning; Green's team is also enriching their platform to help drug developers create nanoparticles that can target specific cells in the body. 
"By fine-tuning small chemical changes, we can steer a nanoparticle to specific tissues and even specific cells," said Green. "This would allow us to develop more precisely delivered therapies, which could improve both efficacy and safety."

About the Author
PhD
Interested in health technology and innovation.
You May Also Like
FEB 24, 2022
Cardiology
Light Drinking is Harmful to the Heart
FEB 24, 2022
Light Drinking is Harmful to the Heart
Even small amounts of alcohol appear to increase the risk of cardiovascular events.
MAR 15, 2022
Clinical & Molecular DX
Streamlining the Diagnosis of Bloodstream Infections: Opportunities for Improvement
MAR 15, 2022
Streamlining the Diagnosis of Bloodstream Infections: Opportunities for Improvement
There are many challenges facing our healthcare system today, but sepsis is undeniably one of the most significant. Seps ...
MAR 08, 2022
Cardiology
Poor Sleep May Nearly Triple Heart Disease Risk
MAR 08, 2022
Poor Sleep May Nearly Triple Heart Disease Risk
Poor sleep has many negative consequences, including a serious impact on heart health.
MAR 15, 2022
Drug Discovery & Development
Moderna begins clinical trial for its second HIV vaccine
MAR 15, 2022
Moderna begins clinical trial for its second HIV vaccine
On Monday, March 14, the biotech company Moderna announced that the first participant had been dosed with a ne ...
APR 22, 2022
Genetics & Genomics
Identifying "Cancer Culprits" in the Genome
APR 22, 2022
Identifying "Cancer Culprits" in the Genome
Most cells carry the complete genome in their nucleus, and as cells divide and age, they can pick up mutations in that g ...
MAY 06, 2022
Technology
Smartphone App Screens for Neurological Conditions Using Pupil Scans
MAY 06, 2022
Smartphone App Screens for Neurological Conditions Using Pupil Scans
Neurological conditions can be devastating. Conditions like Alzheimer’s (which is becoming increasingly common as ...
Loading Comments...